<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8284">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01960504</url>
  </required_header>
  <id_info>
    <org_study_id>C1209</org_study_id>
    <nct_id>NCT01960504</nct_id>
  </id_info>
  <brief_title>First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)</brief_title>
  <acronym>BIOSOLVE-II</acronym>
  <official_title>BIOTRONIK - Safety and Clinical PerFormance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects With de NOvo Lesions in NatiVE Coronary Arteries: BIOSOLVE-II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Netherlands: Dutch Health Care Inspectorate</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Singapore: Health Sciences Authority</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BIOSOLVE-II is a prospective, international, multicenter, First in Man study. The purpose of
      this study is to assess the safety and clinical performance of the drug eluting absorbable
      metal scaffold (DREAMS 2nd Generation).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>In segment Late Lumen Loss</measure>
    <time_frame>6 months post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF), defined as composite of cardiac death, target vessel Q-wave or non-Q-wave Myocardial Infarction (MI), Coronary Artery Bypass Graft (CABG), clinically driven Target Lesion Revascularisation (TLR)</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scaffold thrombosis rate</measure>
    <time_frame>1, 6, 12, 24 and 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-scaffold and in-segment Binary Restenosis Rate</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-scaffold and in-segment Percent Diameter Stenosis</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Lumen Loss in segment</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Lumen Loss in scaffold</measure>
    <time_frame>6 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>During the hospital stay to a maximum of the first seven days post index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Procedure Success defined as achievement of a final diameter stenosis of &lt;30% by QCA, using any percutaneous method, without the occurrence of death, Q-wave or WHO defined non-Q-wave, or repeat revascularization of the target lesion during the hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>Day 0</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Device Success is defined as a final residual diameter stenosis of &lt;30% by QCA, using the assigned device only
successful delivery of the scaffold to the target lesion site in the coronary artery
appropriate scaffold deployment
successful removal of the device
safe removal of the device in case of deployment failure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">121</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>Drug Eluting Absorbable Metal Scaffold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Coronary Intervention (DREAMS) stenting</intervention_name>
    <arm_group_label>Drug Eluting Absorbable Metal Scaffold</arm_group_label>
    <other_name>DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is &gt; 18 years and &lt; 80 years of age

          -  Written subject informed consent available prior to PCI

          -  Subjects with stable or unstable angina pectoris or documented silent ischemia

          -  Subject eligible for PCI

          -  Subject acceptable candidate for coronary artery bypass surgery

          -  Subjects with a maximum of two single lesions in two separate coronary arteries which
             have to be de novo lesions.

          -  Reference vessel diameter between 2.2-3.8 mm by visual estimation

          -  Target lesion length ≤ 21 mm by visual estimation

          -  Target lesion stenosis by visual estimation, assisted by QCA / IVUS:  &gt; 50% - &lt; 100%

          -  Eligible for Dual Anti Platelet Therapy (DAPT)

        Exclusion Criteria:

          -  Pregnant or breast-feeding females or females who intend to become pregnant during
             the time of the study

          -  Evidence of myocardial infarction within 72 hours prior to index procedure

          -  Subjects with a ≥2 fold CK level or in absence of CK a ≥3 fold CKMB level above the
             upper range limit within 24 hours prior to the procedure

          -  Unprotected left main coronary artery disease

          -  Three-vessel coronary artery disease at time of procedure

          -  Thrombus in target vessel

          -  Subject is currently participating in another study with an investigational device or
             an investigational drug and has not reached the primary endpoint yet

          -  Planned interventional treatment of any non-target vessel within 30 days
             post-procedure

          -  Subjects on dialysis

          -  Planned intervention of the target vessel within 6-month after the index procedure

          -  Ostial target lesion (within 5.0 mm of vessel origin)

          -  Target lesion involves a side branch &gt;2.0 mm in diameter

          -  Documented left ventricular ejection fraction (LVEF) ≤ 30%

          -  Heavily calcified lesion

          -  Target lesion is located in or supplied by an arterial or venous bypass graft

          -  The target lesion requires treatment with a device other than the pre-dilatation
             balloon prior to scaffold placement (including but not limited to, rotational
             atherectomy, cutting balloon etc.)

          -  Known allergies to: Acetylsalicylic Acid (ASA), Heparin, Contrast medium, Sirolimus,
             or similar drugs; or the scaffold material

          -  Impaired renal function (serum creatinine &gt; 2.5 mg/dl or 221 mmol/l, determined
             within 72 hours prior to intervention)

          -  Subject is receiving oral or intravenous immuno-suppressive therapy (e.g., inhaled
             steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune
             disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not
             including diabetes mellitus)

          -  Proximal or distal to the target lesion located stenosis that might require future
             revascularization or impede run off detected during diagnostic angiography

          -  Life expectancy less than 1 year

          -  Planned surgery or dental surgical procedure within 6 months after index procedure

          -  In the investigators opinion subjects will not be able to comply with the follow-up
             requirements
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Haude, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Städtische Kliniken Neuss</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Banu Eyueboglu Seitz, PhD</last_name>
    <phone>+41 44 864 5872</phone>
    <email>banu.eyueboglu.seitz@biotronik.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tamara Koch</last_name>
    <phone>+41 44 864 58 77</phone>
    <email>tamara.koch@biotronik.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OLV-Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William Wijns, MD</last_name>
    </contact>
    <investigator>
      <last_name>William Wijns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>São Paulo</city>
        <zip>04012-909</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre Abizaid</last_name>
    </contact>
    <investigator>
      <last_name>Alexandre Abizaid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto do Coração - HCFMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pedro A. Lemos, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pedro A. Lemos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evald Høj Christiansen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Evald Høj Christiansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz-Josef Neumann, MD</last_name>
    </contact>
    <investigator>
      <last_name>Franz-Josef Neumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Segeberg Kliniken GmbH, Herzzentrum</name>
      <address>
        <city>Bad Segeberg</city>
        <zip>D-23795</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Tölg, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ralph Tölg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Städtische Kliniken Neuss - Lukaskrankenhaus</name>
      <address>
        <city>Neuss</city>
        <zip>41464</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Haude, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Haude, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thoraxcentrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7513ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clemens von Birgelen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Clemens von Birgelen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Heart Centre Singapore</name>
      <address>
        <city>Mistri Wing</city>
        <zip>168752</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lim Soo Teik, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lim Soo Teik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nieves Gonzalo Lopez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nieves Gonzalo Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Kaiser, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christoph Kaiser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUV - Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Eeckhout, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Eeckhout, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 23, 2013</lastchanged_date>
  <firstreceived_date>October 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DREAMS</keyword>
  <keyword>Drug Eluting Absorbable Metal Scaffold</keyword>
  <keyword>Scaffold</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Atherosclerosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
